is critical for redox reactions and as a substrate for signaling by the PARPs [poly(adenosine diphosphateribose) polymerases] and the sirtuins (SIRT1 to SIRT7) in the regulation of DNA repair, energy metabolism, cell survival, and circadian rhythms, among other functions (1) (2) (3) . Raising NAD + concentrations or directly activating the sirtuins delays aging in yeast, flies, and mice (4-6). Increased amounts of sirtuin and PARP1 activity are also associated with improved health and longevity in humans (4, 7) . Thus, understanding how cells modulate NAD + and PARP1 activity may shed light on new therapies for major diseases, such as diabetes and cancer, and possibly also the aging process (3, 8) .
Whether NAD + has a third role in cells as a direct regulator of protein-protein interactions is a matter of speculation (9) . The protein DBC1 (deleted in breast cancer 1) is one of the most abundant yet enigmatic proteins in mammals (10, 11) , with a conserved domain similar to Nudix hydrolases that hydrolyze nucleoside diphosphates but lacking catalytic activity due to the absence of key catalytic residues (9, 12, 13) .
DBC1 is known to inhibit SIRT1 (14), so we tested whether DBC1 might also inhibit PARP1 as a way to coregulate these two major NAD + -responsive pathways. In human embryonic kidney (HEK) 293T cells, a SIRT1-independent interaction between DBC1 and PARP1 was detected (Fig. 1A  and fig. S1 , A and B). The PARP1 inhibitors PJ-34 and 3-aminobenzamide (3-AB) had no effect on the interaction ( fig. S1C ), nor did overexpression of the adenosine diphosphate (ADP)-ribose hydrolase MACROD1 (MACRO domain containing 1) ( fig. S1D) S1E ). Thus, PARP1-DBC1 binding is independent of PARP1 catalytic activity.
The PARP1-DBC1 complex was abrogated by NAD + in a concentration-dependent manner, whereas the SIRT1-DBC1 interaction was unaffected within physiological ranges of NAD + (15) , except at 500 mM (Fig. 1B) . This effect was surprisingly specific: 200 mM of nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), adenosine, adenosine triphosphate, and ADPribose, or 500 mM of nicotinamide and its structural analog 3-AB (2 mM), had no effect on the PARP1-DBC1 complex, and NADH (the reduced form of NAD + ) (200 mM) or adenine (200 mM) were less effective than NAD + (Fig. 1C and fig.  S2 , A to C).
DBC1 mutants lacking regions outside the NHD (DBC1 1-500 and DBC1 243-923 ) behaved similarly to full length DBC1 (Fig. 1C) , whereas MACROD1, poly(ADP-ribose) glycohydrolase (PARG) ( fig. S2D), or PARP1 inhibitors (fig. S1C ) had no effect. PARP1-E988K behaved similarly to the wild type ( fig. S1E and fig. S2E ). Carbanicotinamide adenine dinucleotide, a nonreactive PARP1 substrate, abrogated the complex ( fig. S2F) . Thus, disruption of the PARP1-DBC1 complex by NAD + does not require NAD + cleavage or a covalently attached ADP-ribose.
In HEK 293T cells, FK866, an inhibitor of NAD + biosynthesis (16) , increased the PARP1-DBC1 interaction (Fig. 1D) , as did depletion of NAD + by genotoxic stress ( fig. S3A ). Interventions that increased NAD + abundance (5, 17) decreased the PARP1-DBC1 interaction (Fig. 1 , E and F, and fig. S3B ). The SIRT1-DBC1 interaction was slightly diminished by FK866, possibly through the sequestration of DBC1 by PARP1 ( fig. S3C ). Together, these data indicate that NAD + inhibits PARP1-DBC1 complex formation in cells.
To better understand the mechanism by which NAD + inhibits complex formation, we identified the DBC1 domain necessary for interaction with PARP1. A truncated version of DBC1 lacking an NHD conserved region (DBC1 D354 We generated an atomic-resolution homology model for the human DBC1-NHD. Our model is based on five known crystal structures of Nudix domains from other proteins ( Fig. 2A, fig. S7 , and supplementary materials and methods). NAD + had the best fit of all riboside nucleotides. Substitutions of the amino acids predicted to alter NAD + binding inhibited PARP1-DBC1 binding either slightly (K353A and P366A) or substantially (Q391A) (Fig. 2B and fig. S8, A and B) . Radio-labeled or biotin-labeled NAD + directly bound to DBC1 (Fig. 2, C and D) and was competed off with unlabeled NAD + ( fig. S9 , A to D). Partial deletion of the NHD (DBC1 D354-396 ) or Q391A (DBC1 Q391A ) reduced NAD + binding, whereas Nterminal and C-terminal truncations did not (Fig.  2, C to D, and fig. S9E ). Mutation of C387, a residue close to Q391 on the same helix ( Fig. 2A) , also decreased NAD + binding (Fig. 2D ) and reduced the responsiveness of the PARP1-DBC1 complex to NAD + (Fig. 2E ). PARP1 activity was inhibited by DBC1 in vitro (Fig. 3A) . In cells, knocking down DBC1 increased both PAR [poly(ADP-ribose)] concentrations before and after exposure to paraquat, H 2 O 2 , or etoposide (Fig. 3B and fig. S10, A to D) and the abundance of mRNAs positively regulated by PARP1 (Fig. 3C) (19, 20) . Reintroduction of wildtype DBC1 reduced PARP1 activity and partially restored gene expression, whereas DBC1 Q391A had no effect (Fig. 3C and fig. S10, E and F) . Reducing DBC1 lowered the abundance of the phosphorylated form of histone H2AX (gH2AX) (Fig. 3D) , reduced DNA fragmentation (Fig. 3E  and fig. S11A ), increased cell survival after paraquat treatment ( fig. S11B) , and increased both nonhomologous end joining (NHEJ) and homologous recombination (HR) pathways in a PARP1-dependent manner (Fig. 3F and fig. S11C ). Similarly, NMN treatment reduced the number of gH2AX foci in paraquat-treated primary human fibroblasts (Fig.  3G and fig. S12 ). No other major DNA repair proteins appeared to change their interactions with the PARP1-DBC1 complex in the presence of NMN or DNA damage (fig. S13, A and B that a cause may be increased binding of DBC1 to PARP1 as NAD + levels decline during aging. To test this, we examined the effect of NMN treatment on young and old mice. Hepatic NAD + concentrations were lower in old mice (Fig. 4A) , coincident with a higher amount of the DBC1-PARP1 complex (Fig. 4B ) and an increase in gH2AX staining (Fig. 4C and fig. S14 ). A week of NMN treatment (500 mg/kg per day intraperitoneally) increased hepatic NAD + concentrations and disrupted the PARP1-DBC1 complex in young ( fig. S15, A and B) and old mice (Fig. 4, D and E) and reduced the abundance of gH2AX in old mice (Fig. 4C and fig. S14 ).
Old mice had lower levels of PARP1 activity (Fig. 4F and fig. S16A ) and a decreased response to DNA damage ( fig. S16B) , and DBC1 knockout mice had increased PARP1 activity (Fig. 4G and  fig. S16C ). The reduced PARP1 activity in the old mice was restored by NMN (Fig. 4F and fig. S16D ) but not if PARP1 activity was inhibited (fig. S16, E and F). Total amounts of poly(ADP-ribosylation) increased with age in the liver (4), possibly due to reduced PARG abundance ( fig. S17A ). These data indicate that the decline in NAD + during aging promotes the binding of DBC1 to PARP1, which inhibits PARP1's ability to mediate DNA repair. Similar studies were conducted on old mice exposed to gamma irradiation. NMN treatment (Fig. 4E ) reduced DNA damage (Fig. 4H and fig. S17 , B and C) and protected against alterations in white blood cell counts, lymphocytes, and hemoglobin, even when given after irradiation (Fig. 4, I and J, and fig. S18, A to C) .
These data show that NAD + has a third function in cells: to directly regulate protein-protein interactions. We speculate that this mechanism evolved to allow a cell to adapt to fluctuations in NAD + abundance without degrading it and, in the case of DBC1, to serve as a negative-feedback loop to prevent PARP1 from depleting NAD + down to lethal levels during DNA damage (15) ( fig. S19 ). The data also provide an explanation for why DBC1 mutations are associated with cancers (22) , Sidak's post-hoc correction. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant. tumors will help inform ongoing clinical trials of PARP1 inhibitors for treating cancer (23) . Although the reason NAD + declines with age is unclear, this work provides a plausible explanation for why DNA repair capacity declines as we age (24) , pointing to NAD + replenishment as a means of reducing the side effects of chemotherapy, protecting against radiation exposure, and slowing the natural decline in DNA repair capacity during aging.
